Shattering barriers toward clinically meaningful MSC therapies-Reference-Cited by-同舟云学术

Shattering barriers toward clinically meaningful MSC therapies

Published:2020-07-24 Issue:30 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Levy Oren¹^ORCID,Kuai Rui¹²^ORCID,Siren Erika M. J.¹^ORCID,Bhere Deepak²³^ORCID,Milton Yuka¹,Nissar Nabeel³^ORCID,De Biasio Michael¹^ORCID,Heinelt Martina¹,Reeve Brock⁴^ORCID,Abdi Reza⁵^ORCID,Alturki Meshael⁶⁷,Fallatah Mohanad⁷,Almalik Abdulaziz⁶⁷,Alhasan Ali H.⁶⁷^ORCID,Shah Khalid²³⁴^ORCID,Karp Jeffrey M.¹²⁴⁸^ORCID

Affiliation:

1. Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA.

2. BWH Center of Excellence for Biomedicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

3. Center for Stem Cell Therapeutics and Imaging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

4. Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.

5. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

6. National Center of Pharmaceutical Technology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.

7. KACST Center of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.

8. Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Abstract

To realize the potential of MSCs, bioengineering is needed to boost potency and control heterogeneity.

Funder

National Institutes of Health

King Abdulaziz City for Science and Technology

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference177 articles.

1. Fibroblast precursors in normal and irradiated mouse hematopoietic organs;Friedenstein A. J.;Exp. Hematol.,1976

2. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC

3. A study of CYP-001 for the treatment of steroid-resistant acute graft versus host disease; https://clinicaltrials.gov/ct2/show/NCT02923375.

4. Prochymal® (human adult stem cells) intravenous infusion following acute myocardial infarction (AMI); https://clinicaltrials.gov/ct2/show/NCT00877903.

5. Safety and efficacy of intravenous autologous mesenchymal stem cells for MS: A phase 2 proof of concept study (MESCAMS); https://clinicaltrials.gov/ct2/show/NCT02239393.

Cited by 423 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MSCs biomimetic ultrasonic phase change nanoparticles promotes cardiac functional recovery after acute myocardial infarction;Biomaterials;2025-02

2. Efficiently directing differentiation and homing of mesenchymal stem cells to boost cartilage repair in osteoarthritis via a nanoparticle and peptide dual-engineering strategy;Biomaterials;2025-01

3. An examination of process models and model risk frameworks for pharmaceutical manufacturing;International Journal of Pharmaceutics: X;2024-12

4. CEACAM1-engineered MSCs have a broad spectrum of immunomodulatory functions and therapeutic potential via cell-to-cell interaction;Biomaterials;2024-12

5. MicroRNA-based engineered mesenchymal stem cell extracellular vesicles to treat visual deficits after blast-induced trauma;Experimental Eye Research;2024-10